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Summary
 
Monoclonal antibodies (mAbs) to the polysaccharide capsule of 
 
Cryptococcus neoformans
 
 can pro-
long survival in mice. However, the properties of antibodies that mediate protection are not
fully understood. The IgM mAbs 12A1 and 13F1 originated from the same B cell and differ
only by somatic mutations in their variable regions; yet mAb 12A1 protects against serotype D
infection, while mAb 13F1 does not. Phage peptide display libraries were used to analyze the
fine specificity of these two mAbs. The selection of distinct peptide motifs from identical li-
braries confirmed that mAbs 12A1 and 13F1 bound to two distinct epitopes. Immunofluores-
cence and immunoelectron microscopy studies revealed differences in antibody localization
within the capsule of serotype D strain; mAb 12A1 bound to the outer rim of the capsule re-
sulting in an annular pattern, whereas mAb 13F1 bound throughout the capsule and had a
punctate appearance. The difference in the binding pattern of mAb 12A1 and 13F1 was not
observed on serotype A organisms, where both mAbs bound to the capsule with an annular
fluorescence pattern. The fluorescence pattern of binding correlated with protective efficacy;
mAb 13F1 prolonged survival of mice infected with the J11 serotype A strain (annular fluores-
cence), but not serotype D strains (punctate pattern). Annular binding, but not punctate bind-
ing, was associated with increased opsonic efficacy for phagocytosis of 
 
C. neoformans
 
 by J774.16
macrophage-like cells. The correlation between capsular binding pattern, opsonic activity, and
ability to prolong survival suggests that the efficacy of anticryptococcal antibodies is dependent
upon where they bind in the polysaccharide capsule.
 
T
 
he concept of protective and nonprotective epitopes
emerged from studies on the interaction of viruses with
particular antibodies (1). The efficacy of mAbs in modulat-
ing bacterial infections can depend on the epitope that the
mAb binds to the bacterial surface (2). While the value of
antibodies in the host defense against bacteria and viruses is
accepted, the role of antibodies against medically important
fungi remains controversial (3). Much of the initial evi-
dence supporting or contradicting a role for antibodies in
the defense against fungi relied on experiments using poly-
clonal sera which contained complex mixtures of antibodies
differing in epitope specificity and isotype, both of which
may determine antibody efficacy (3). More recently, using
mAbs, protective, and nonprotective antibodies to 
 
Candida
albicans
 
 and 
 
Cryptococcus neoformans
 
 have been identified (4, 5).
 
C. neoformans
 
 frequently causes a fatal meningoencepha-
litis in patients with AIDS. In New York City alone, there
were over 1,200 cases in 1991, with a prevalence of infection
in patients with AIDS is 6–8% (6). Many cases are incurable
because antifungal therapy fails to eradicate infection in the
setting of severe immunosuppression. 
 
C. neoformans
 
 is un-
usual among fungi in that it has a polysaccharide capsule.
The polysaccharide capsule blocks phagocytosis (7) and the
capsular polysaccharide is shed into the circulation and tis-
sues during infection. Soluble polysaccharide may contrib-
ute to virulence by suppressing the immune response (8),
inhibiting leukocyte migration (9), and enhancing HIV in-
fection (10). mAbs that bind the polysaccharide capsule can
enhance in vitro phagocytosis (11), reduce serum polysac-
charide (5), and prolong in vivo survival in murine infec-
tion models (12). We have previously demonstrated that
antibody isotype and epitope specificity are important de-
terminants of antibody protective efficacy. For example,
murine IgG3 antibodies enhance infection and block IgG1-
and IgG2a-mediated protection (13, 14).
A role for epitope specificity in determining protective
efficacy was suggested by experiments with two murine
IgM anticryptococcal mAbs, 12A1 and 13F1. These mAbs
originated from the same B cell but differed in their reac-
tivity with cryptococcal polysaccharide and their ability to
prolong the survival of mice lethally infected with a sero-
type D strain (5). mAbs 12A1 and 13F1 were generated in
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response to immunization with glucuronoxylomannan
(GXM)
 
1
 
, the primary component of the cryptococcal polysac-
charide capsule, conjugated to tetanus toxoid (GXM-TT).
Their V
 
H
 
 regions differ by five amino acids in the first and
second CDRs and three amino acids in framework regions,
and their V
 
L
 
 regions differ by one amino acid in CDR1,
one amino acid in CDR2, and three amino acids in frame-
work regions (15). Indirect immunofluorescence revealed
differences in binding to the polysaccharide capsule by
mAbs 12A1 and 13F1 (5). The protective mAb, 12A1, pro-
duced a homogeneous annular fluorescence pattern, whereas
the nonprotective mAb, 13F1, produced a punctate pattern
of fluorescence on one strain of serotype D, 
 
C. neoformans.
 
Because these preliminary observations seemed to indi-
cate structural heterogeneity in the capsule of serotype D or-
ganisms that was associated with the protective efficacy of
antibodies, we studied other strains of 
 
C. neoformans
 
 repre-
senting all serotypes. We report here that the antibody
binding pattern differed among the four 
 
C. neoformans
 
 sero-
types and that the location of IgM binding appears to be
critical for protective efficacy, suggesting a relationship be-
tween the ability to confer protection and the location of
antibody binding to the cryptococcal capsule. Since oli-
gosaccharides are not available to define the chemical struc-
ture of the protective and nonprotective polysaccharide
epitopes, we screened phage peptide display libraries with
mAbs 12A1 and 13F1 and defined peptide binding motifs
that distinguished the binding sites of the two antibodies.
Selected peptides were used to probe the antibody-binding
pocket and confirmed differences in the fine specificity of
mAbs 12A1 and 13F1.
 
Materials and Methods
 
C. neoformans.
 
Strains 24064, 24065, 24067, 32608, 34873,
and 34874 were obtained from the American Type Culture Col-
lection (Rockville, MD). Strains J11, J22, and SB6 were isolated
from the cerebrospinal fluid of patients with cryptococcal menin-
gitis and have been described (16). Strain National Institutes of
Health 371 was obtained from Dr. J.E. Bennett (Bethesda, MD).
All strains were maintained on Sabouraud dextrose agar slants
(Difco Labs., Detroit, MI) and grown in Sabouraud dextrose broth
(Difco Labs.) at 37
 
8
 
C before use. (For strain serotypes see Table 2.)
 
mAbs.
 
mAbs 12A1, 13F1, and 21D2 were described previ-
ously (17, 18). Ascites was generated by injecting 10
 
7
 
 hybridoma
cells into the peritoneal cavity of pristane primed BALB/c mice.
Antibody concentration was determined by ELISA relative to
isotype-matched standards of known concentration. Lipid was
removed from ascites samples (Cleanascite; Affinity Technology
Inc., New Brunswick, NJ) and ascites was used directly in pro-
tection experiments. For in vitro phagocytosis and phage ELISA
studies, IgMs were purified by mannose-binding protein affinity
chromatography (Pierce Chem. Co., Rockford, IL).
 
Selection of 12A1 and 13F1 Binding Phage.
 
Antibody binding
phage were isolated from random hexapeptide and decapeptide li-
braries by multiple cycles of selection and amplification (19). The
hexapeptide library was reamplified from an aliquot provided by
Dr. George Smith (University of Missouri, Columbia, MO). We
constructed the decapeptide library with the filamentous phage
fUSE5 vector (20). In the initial screening, mAbs 12A1 and 13F1
were attached to streptavidin-coated magnetic beads (Adv. Magnet-
ics, Inc., Cambridge, MA) with a biotinylated anti–mouse IgM
antibody (Southern Biotechnology Assoc., Birmingham, AL). All
incubations were at room temperature in biopanning buffer
(BPB) (10 mM Tris/HCl, pH 7.5, 150 mM NaCl, 0.1% (wt/vol)
BSA, 0.1% (vol/vol) Tween 20, and 0.02% (wt/vol) NaN
 
3
 
) with
slow end-over-end rotation. 0.2 
 
m
 
M IgM was first incubated for
30 min with 1.5 
 
m
 
g of biotinylated anti–mouse IgM antibody in
50 
 
m
 
l BPB. The mixture was transferred to a microfuge tube
containing 50 
 
m
 
l of streptavidin-coated beads (storage solution
was removed with a magnet from Dynal, Oslo, Norway). After
30 min, the beads were vortexed and the remaining biotin bind-
ing sites were blocked with 1.5 
 
m
 
l of D-biotin (10 mM) for 10
min. The beads were washed three times with 500 
 
m
 
l BPB, and
then incubated for 4 h with 200 equivalents of peptide library
(4 
 
3
 
 10
 
10
 
 transducing units [TU] for the hexapeptide library and
8 
 
3
 
 10
 
10
 
 TU for the decapeptide library [sublibraries L102 and
L103]; reference 20). The beads were washed seven times with
BPB during which they were transferred three times to new sili-
conized microfuge tubes. Bound phage particules were eluted at
pH 2.2 as described (21). Phage titration, amplification, and poly-
ethylene glycol purification were done according to Smith and
Scott (22). For subsequent rounds of selection, 
 
z
 
1 
 
3
 
 10
 
9
 
 TU
from the preceding round were first incubated for 4 h with lower
concentrations of IgM mAb, and then phage antibody complexes
were captured for 10 min by the addition of 10 
 
m
 
l streptavidin-
coated magnetic beads saturated with 3 
 
m
 
g biotinylated anti–
mouse IgM antibody.
 
Sequence Determination of Displayed Peptides.
 
Phage DNA was
purified by extraction of the virion preparation with phenol and
chloroform, and re-suspended in 7 
 
m
 
l of water after ethanol pre-
cipitation. Dideoxy sequencing reactions (23) were performed us-
ing the Sequenase kit (United States Biochemical Corp., Cleve-
land, OH) with a 
 
32
 
P end-labeled 18-base fUSE5 primer (22).
Termination reactions were started directly in microwells of micro-
testing plates (Robbins Scientific Corp., Sunnyvale, CA). Samples
were run on polyacrylamide gels (6% monomer) using Sequagel
sequencing reagents (National Diagnostics, Inc., Atlanta, GA).
 
Phage ELISA.
 
Antibody reactivity with phage was detected
by the “direct” ELISA as described (24). In brief, phage were pre-
pared from overnight cultures by two polyethylene glycol precip-
itations according to published methods (22). Phage were cap-
tured on the ELISA plate using an anti-m13 antibody (5 Prime–3
Prime, Inc., Boulder, CO). Phage (5 
 
3
 
 10
 
10
 
 virions) were incu-
bated in the ELISA well for 2 h, and after washing, mAb (0.5 
 
m
 
g/ml)
was incubated with phage for 2 h. After washing, anti–mouse
IgM antibody conjugated to alkaline phosphatase was added and
incubated for 1 h. Phosphatase substrate 
 
p
 
-nitrophenyl phosphate
(Sigma Chemical Co., St. Louis, MO) was dissolved in diethano-
lamine buffer, pH 9.8, to a concentration of 1 mg/ml and 50 
 
m
 
l/
well were added to the plates. Absorbance at 405 nm was mea-
sured in a microplate reader (EL 320; Biotek Instrument Inc.,
Winooski, VT) after 1 h of incubation at 37
 
8
 
C. Each test was
done in duplicate, and the absorbance given by the control phage
was subtracted. Phage 
 
f
 
673 is a randomly selected recombinant
phage bearing the sequence RKVWVI which was used as a con-
trol in the hexapeptide phage ELISAs. Phage 
 
f
 
33 does not con-
tain an insert and was used as a control phage in the decapeptide
phage ELISAs.
 
1
 
Abbreviations used in this paper:
 
 BPB, biopanning buffer; GXM, glucuron-
oxylomannan; GXM-TT, GXM conjugated to tetanus toxoid; IEM, im-
munoelectron microscopy; TU, transducing units. 
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Indirect Immunofluorescence.
 
Stationary phase organisms were
washed three times in PBS, and 1 
 
3
 
 10
 
6
 
 organisms were placed
into microfuge tubes. mAb was added to the organisms (5 
 
m
 
g/ml)
and incubated at room temperature for 1.5 h (identical results
were obtained at 4
 
8
 
C). An IgM standard (Organon Teknika,
Durham, NC) was used as a negative control. Organisms were
collected by centrifugation, washed twice in PBS/1% (wt/vol)
BSA, and resuspended in FITC-labeled goat anti–mouse IgM an-
tibody (Southern Biotechnology Assoc.) for 1 h at room temper-
ature in the dark. Organisms were washed twice in PBS/BSA and
resuspended in 50 ml mounting media (50% [vol/vol] glycerol/
PBS, 0.1 M 
 
n
 
-propyl gallate) (Sigma Chemical Co.). The suspen-
sion was mounted on poly-
 
l
 
-lysine–coated slides (Sigma Chemi-
cal Co.) and viewed with a Zeiss phase contrast microscope
equipped with a FITC filter or with a confocal microscope
(MRC 600; BioRad Labs., Hercules, CA) using Nikon 
 
3
 
60 nu-
merical aperture 1.4 planapochromat optics and a Kr/Ar laser.
For confocal microscopy, 16 optical sections were collected at 0.8
 
m
 
m intervals and imaged by the maximum projection method.
Confocal microscopy was carried out (Analytical Imaging Facility
of the Cancer Center of the Albert Einstein College of Medicine,
New York).
 
Immunoelectron Microscopy.
 
Cryptococci were prepared for
immunoelectron microscopy (IEM) in the same manner as for
immunofluorescence. Goat anti–mouse IgM antibody coupled to
10 nm gold balls (E-Y Laboratories, Inc., San Mateo, CA) was di-
luted 1:30 in PBS/BSA and centrifuged for 2 min after which the
supernatant was used. Organisms coated with IgM mAbs 12A1,
13F1, and an irrelevant IgM used as a negative control were re-
suspended in 100 
 
m
 
l gold labeled antibody for 1 h at room tem-
perature. Labeled organisms were washed and resuspended in
electron microscopy fixative (Trumps solution composed of 1%
[vol/vol] glutaraldehyde and 4% [vol/vol] paraformaldehyde in
PBS), embedded in plastic, cut into sections, and examined in the
Analytical Imaging Facility of the Cancer Center of the Albert
Einstein College of Medicine.
 
Animal Studies.
 
All protection experiments were done using
female A/J mice aged 6–8 wk (Jackson Labs., Bar Harbor, ME).
mAb (1 mg per mouse) was administered intraperitoneally 
 
z
 
30
min before infection. 
 
C. neoformans
 
 infection was induced by in-
traperitoneal inoculation using an inoculum of 1 
 
3
 
 10
 
8
 
 yeast cells
for the serotype D experiment and 3 
 
3
 
 10
 
7
 
 yeast cells for the se-
rotype A experiment. Deaths were recorded daily and data was
analyzed by log-rank analysis (Instat version 2.01 for Macintosh;
GraphPAD Software for Sci., San Diego, CA).
 
Phagocytosis Assay.
 
The ability of mAbs 12A1 and 13F1 to
promote phagocytosis of 
 
C. neoformans
 
 strains 24067 and J11 was
studied using the J774.16 cells as described (11, 25). In brief,
J774.16 cells were plated on tissue culture plates (No. 3695; Cos-
tar Corp., Cambridge, MA) and stimulated with 500 U of IFN-
 
g
 
(Genzyme Corp., Cambridge, MA) and 3 
 
m
 
g/ml of LPS (Sigma
Chemical Co.). 
 
C. neoformans
 
 was washed and resuspended in
sterile PBS before adding to the J774.16 monolayers in a mac-
rophage to yeast ratio of 1:1, with either mAb 12A1 or 13F1.
The suspension was incubated for 2 h at 37
 
8
 
C. The J774.16
monolayers were then washed several times with PBS to remove
nonadherent organisms, fixed with cold absolute methanol, and
stained with a 1:20 solution of Giemsa (Sigma Chemical Co.).
The phagocytic index is the number of internalized yeast per
number of macrophages per field. For each mAb, five to six fields
were counted, each containing at least 200 cells. Previous studies
with diaethanol staining and electron microscopy have established
that light microscopy can distinguish between internalized and at-
tached yeast cells (11). Phagocytic indices were determined with
a microscope at the magnification of 
 
3
 
600 (Nikon Diaphot; Ni-
kon Inc., Instr. Group, Melville, NY).
 
Results
 
Peptide Mimotopes Selected by mAbs 12A1 and 13F1.
 
While the results presented in previous studies (5) strongly
suggested that mAbs 12A1 and 13F1 bound to different
epitopes, differences in their fine specificity could not be
confirmed using oligosaccharides since none have been
identified that react with antibodies to the capsular polysac-
charide. As an alternative, we screened phage libraries con-
taining either 6 or 10 random amino acid inserts in the pIII
coat protein of filamentous phage fd (19). After three
rounds of selection from the hexapeptide library with 0.2 
 
m
 
M
IgM, mAb 12A1 selected two phage with related peptide
sequences (
 
f
 
M1 and 
 
f
 
M2) which differ at 2 positions (Ta-
ble 1). mAb 13F1 selected two unrelated peptide sequences
that did not bind 13F1 in the phage ELISA (sequences not
shown). The low ELISA signals and the lack of sequence
diversity in the selected peptides suggested that a larger pep-
tide was required to find higher binding motifs, a conclu-
sion that we had already come to with the related mAb
2H1 (20).
We therefore screened a decapeptide phage library. After
a first round with each mAb at 0.2 
 
m
 
M and a second at 0.2
nM, the phage yield for 12A1 was 1.2% in the presence of
antibody compared to 0.06% without antibody, and for
13F1, 33% compared to 0.03% without antibody. Ran-
domly selected phage were sequenced at this point and af-
ter a third round of screening using 20 pM IgM to capture
higher affinity peptides. A few phage peptide sequences had
two cysteines like 
 
f
 
M5 (FNVCFPFCTG, 12A1), 
 
f
 
M6 (FKF
CEWYGPC, 12A1), or 
 
f
 
M23 (YTWYCWEEWC, 13F1),
and presumably represented constrained peptides but did not
provide dominant motifs (not shown in Table 1). How-
ever, the predominant feature of most of the sequenced
phage was three aromatic amino acids, each separated by a
nonaromatic residue. Such a motif was previously noted in
phage selected by the closely related mAb 2H1 (20). The
presence of this motif was used together with antibody re-
activity to group the peptide sequences. Group 1 contains
phage 
 
f
 
M1 and 
 
f
 
M2 from the hexapeptide library and
 
f
 
M8 and 
 
f
 
M9 from the decapeptide library. The three ar-
omatic positions have a mixture of tyrosines and trypto-
phans and a glutamate predominates at the COOH-termi-
nus (Table 1). Phage of this group only react with mAb
12A1. Group 2 phage have only tryptophans at their aro-
matic positions, a constant leucine between the first two tryp-
tophans, and a high predominance of glutamate between
the last two tryptophans. Phage of this group only react
with mAb 13F1. Phage 
 
f
 
M4 was isolated by mAb 12A1, but
only reacted by ELISA with mAb 13F1, confirming that a
lower binding affinity threshold was required for selection
than for the phage ELISA. The third group contains phage
having three tryptophans (except 
 
f
 
M30) and an extension
of the constant amino acid positions at the NH
 
2
 
 terminus 
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with two aliphatic residues (except 
 
f
 
M19). These phage
react with both mAbs 12A1 and 13F1, often giving similar
absorbance.
The relationship between mAbs 12A1 and 13F1, and
mAb 21D2, another IgM which binds to the capsule in a
punctate pattern (see below), was analyzed further by cross-
screening; libraries that had been selected by either 12A1 or
13F1 were then submitted to two rounds of selection first
with 0.2 
 
m
 
M and then with 2 nM of 21D2. Phage yields
were 3–4% on the last round (only 0.001% for control, in
absence of antibody). The sequences of these doubly se-
lected phage fell in to group 3 (Table 1) apart from some
clones with unrelated inserts (not shown). This new set of
sequences refined the consensus motif of group 3 phage.
The residue between the two last tryptophans is mainly a
methionine, a glutamine, or an aspartate. In the latter case,
the second tryptophan is no longer required.
 
12A1 and 13F1 Binding Pattern on C. neoformans.
 
In pre-
vious studies, we demonstrated that IgM mAb 12A1 pro-
tected mice from lethal infection with a serotype D strain
(24067; American Type Culture Collection), whereas IgM
mAb 13F1 did not (5). Indirect immunofluorescence experi-
ments revealed that mAbs 12A1 and 13F1 produced annu-
lar and punctate fluorescence patterns, respectively, sug-
gesting that each antibody bound to a different antigenic
structure in the cryptococcal capsule. To further explore this
finding, we examined additional serotype D strains and sev-
eral strains representing the other serotypes (Table 2 and
Fig. 1). mAb binding to strains 34873 and 34874 was simi-
lar to strain 24067; the protective mAb 12A1 bound with
an annular fluorescence pattern, whereas the nonprotective
mAb 13F1 produced a punctate fluorescence pattern (Fig.
1, 
 
top
 
). However, both 12A1 and 13F1 bound in an annu-
lar pattern to a fourth serotype D strain, J22 (Table 2). J22
is an unusual strain with an unstable karyotype (26) and a
GXM structure containing a novel triad repeat (16).
 
Table 1.
 
12A1 and 13F1 Selected Phage Derived from the ArXArXAr Motif
 
Phage Selection
Absorbance
Peptide Sequences 12A1 13F1 21D2
 
Ar X Ar X Ar
 
OD
 
Group 1 Y/W X Y/W X Y/W (E)
 
f
 
M1 Y D W L M F 12A1 0.70
 
,0.1 ,0.1
fM2* Y D W L Y E 12A1 0.24 ,0.1 ,0.1
fM8 YF W N Y S Y E VF 12A1 .2.0 ,0.1 ,0.1
fM9 SY W S S S W E LY 12A1 ND ND ND
Group 2 W L W (E) W
fM4 FD W L W L W DT 12A1 ,0.1 0.9 ,0.1
fM14 LQ W L W E W PRT 13F1 ,0.1 1.61 ,0.1
fM15 LD W L W E W AEQ 13F1 ,0.1 .2.0 ,0.1
fM16 THD W L W E W AS 13F1 ,0.1 0.26 ,0.1
fM17 LS W L W E W ELS 13F1 ND ND ND
fM18 LLDYG W L W M W 13F1 ,0.1 1.47 ,0.1
Group3 V/AV/I W X W X W
fM3 S V I W S W M W LD 12A1 1.51 1.50 0.76
fM25 A V W E W M W WDA 13F1/21D2 0.41 0.59 0.36
fM30 YK A I W L Y M W I 12A1/21D2 0.20 0.27 0.14
fM31 A V W Q W M W VEY 12A1/21D2 0.68 0.79 0.72
fM36 RA V I W A W M W E 12A1 .2.0 .2.0 0.31
fM26 PF V V W D W Q W L 13F1/21D2 ,0.1 0.12 ,0.1
fM35 NM V I W D W Q W T 12A1 0.34 0.16 0.15
fM19 R L W I W A W NVG 13F1 0.67 0.74 ,0.1
V/AV/I W X X D W
fM22 RV V I W A K D W E 13F1 0.97 0.87 0.13
fM24 GLY V I W S R D W 3 mAbs 0.58 0.76 0.38
fM29 YMG A I W A G D W 12A1/21D2 0.25 0.39 0.24
fM32 LRY V V W A D D W 12A1/21D2 0.21 0.33 0.15
*This clone has an insert sequence identical to fG3 isolated by 2H1 (20).689 Nussbaum et al.
In contrast to their different pattern of binding to most
serotype D organisms, both mAbs 12A1 and 13F1 pro-
duced an annular fluorescence pattern on three serotype A
strains and on one serotype A/D strain which contains GXM
structures that are characteristic of both serotypes (Table 2
and Fig. 1). On a serotype B strain, both mAbs produced
annular immunofluorescence patterns. On a serotype C
strain, both mAbs produced a punctate fluorescence pattern.
To more precisely localize antibody binding, mAb bind-
ing to serotype D strain 24067 was studied by IEM (Fig. 2).
Under these conditions, the capsule appeared to have
structural heterogeneity with a denser outer rim linked to
the cell wall by what could be described as spokes. Consis-
tent with confocal microscopy, mAb 12A1 binding con-
centrated to sites at the outer rim of the polysaccharide
capsule (Fig. 2 A). In contrast, mAb 13F1 binding was dis-
tributed throughout the capsule starting at the outer rim,
penetrating deeper into the capsule along the spokes, and
reaching sites almost adjacent to the fungal cell wall (Fig.
2 B). It is important to note that, although the antibodies
were added before fixation, the capsule is fixed and dehy-
drated for electron microscopy, making it difficult to com-
pare the location of the antibodies in fluorescence and elec-
tron microscopy studies.
Binding Patterns of Other Anti-GXM mAbs. To determine
if other GXM-binding antibodies produced a punctate flu-
orescence pattern, we screened sixteen mAbs similar to
12A1 and 13F1 in their variable region sequences, and rep-
resenting all isotypes except IgE. Except for the IgM mAb
21D2, all produced an annular binding pattern on both se-
rotypes D and A, identical to the pattern produced by mAb
12A1. This included the remaining seven members of the
12A1/13F1 hybridoma genealogy that originated from a
single B cell precursor, which share identical heavy and
light chain CDR3 sequences and differ in a limited number
of amino acids predominantly in heavy chain CDR2 (15)
as well as mAbs from other fusions. IgM mAb 21D2 was
isolated from a BALB/c mouse infected with a clinical iso-
late of C. neoformans (undetermined serotype) and uses a
different member of the VH 7183 family than 12A1 and
13F1, but the same VK (18). This mAb had previously been
shown to confer minimal protection against infection with
serotype D strain 24067, with an average survival of 5 d
versus 4 d for PBS alone (17). mAb 21D2 produces a punc-
tate pattern on serotype D strain 24067 and an annular pat-
tern on serotype A strain J11 (data not shown).
mAb Protective Efficacy Against C. neoformans. We first ex-
amined the ability of mAbs 12A1 and 13F1 to modify the
course of infection with serotype D strain 34873 which had
not been tested previously. Intraperitoneal administration
of mAb 13F1 before infection decreased survival relative to
controls (P 5 0.0149), whereas mAb 12A1 prolonged sur-
vival (P 5 0.0396 compared to controls) (Fig. 3 A). In
addition, the animals which received mAb 13F1 died
within a short time of each other (SD 0.88), in contrast to
the saline controls which died over a more extended period
(SD 9.53). This was similar to the previous protection ex-
periment with serotype D strain 24067 where the standard
deviations were 0.37 and 2.53 d for 13F1 and saline con-
Table 2. Indirect Immunofluorescence Capsular Pattern by
mAbs 12A1 and 13F1
Strain* Serotype
Fluorescence pattern
12A1 13F1
24067 D Annular Punctate
34873 D Annular Punctate
34874 D Annular Punctate
J22‡ D Annular Annular
371 A Annular Annular
J11 A Annular Annular
24064 A Annular Annular
SB6 A/D Annular Annular
24065 B Annular Annular
32608 C Punctate Punctate
*Cryptococcal strains are from the American Type Culture Collection,
except J11 and J22 which are clinical isolates from New York City, SB6
which is a clinical isolate from Stony Brook, NY, and 371 which is an
environmental isolate from Thailand.
‡This strain shows evidence of karyotype instability (26) and a novel
GXM component observed in the nuclear magnetic resonance spec-
trum (16).
Figure 1. Indirect immunofluorescence capsular pattern with mAbs
12A1 and 13F1 on different C. neoformans serotype A and D strains.690 Epitope Location in Cryptococcus neoformans and Antibody Efficacy
trols, respectively (5). This may reflect enhanced infection
in the presence of 13F1.
The fact that on serotype A, both mAbs 12A1 and 13F1
bind with the annular pattern observed for 12A1 on most
serotype D organisms while 12A1 prolongs survival, raised
the possibility that both mAbs would protect against sero-
type A infection. We tested this hypothesis using serotype
A strain J11 (Fig. 3 B). mAb 13F1 significantly prolonged
survival of mice infected with this strain compared to saline
controls (P 5 0.001). mAb 12A1 prolonged survival (P 5
0.053), but the increase narrowly missed significance at the
P 5 0.05 level. Nevertheless, mAb 13F1 clearly differs in
its ability to confer protection against the strains represent-
ing the A and D serotypes that we have tested since it pro-
longs survival of animals infected with the J11 A strain and
enhances infection with the 34873 D strain.
Phagocytosis Assays. mAbs 12A1 and 13F1 were tested
for their ability to promote opsonization of organisms by
macrophages. mAb 12A1 significantly enhanced phagocy-
tosis when added to monolayers of J774.16 and strain 24067
cells (Fig. 4 A). Using the same conditions, 13F1 did not
enhance phagocytosis, even at concentrations as high as 25
Figure 2. Immunoelectron micrograph of the cryptococcal serotype D
strain 24067 capsule immunostained with gold-labeled (A) 12A1 and (B)
13F1.
Figure 3. Survival of A/J mice after intraperitoneal treatment with the
IgM mAbs 12A1 and 13F1 preceding infection with C. neoformans. (A) sero-
type D strain 34873, (B) serotype A strain J11.691 Nussbaum et al.
mg/ml. With the J11 serotype A organisms and low anti-
body concentrations, 12A1 was still more effective than
13F1. However, above 10 mg/ml, both mAbs promoted
significant phagocytosis (Fig. 4 B). Annular binding is
therefore associated with more effective opsonization than
punctate binding.
Discussion
We recently showed that mAbs 12A1 and 13F1, two
IgM anti-GXM antibodies with the same apparent avidity,
were quite different in their ability to prolong the life of
mice infected with strain 24067 serotype D C. neoformans
(5). These differences in protection were attributed to dif-
ferences in epitope specificity and were associated with dif-
ferent patterns of capsular binding. Cryptococcal polysac-
charide is composed of a linear (1®3)-a-d-mannopyranan
substituted with b-d-glucopyranosyluronic acid and vary-
ing degrees of b-d-xylopyranosyl and 6-O-acetyl groups, de-
pending on the serotype. The order of reactivity with GXM
from the four serotypes for mAb 12A1 is A.B.D.C, and
for mAb 13F1 it is A.B.C.D (27). The relative degree
of xylose substitution among the C. neoformans serotypes is
C.B.A.D, and the degree of O-acetylation is A.B.
D.C (28). Thus, it is not possible to identify the mAb
epitope on the basis of reactivity with GXM of the differ-
ent serotypes. Epitope analysis is further complicated by the
difficulty in generating oligosaccharide subunits of GXM
capable of inhibiting mAb binding.
To compare the fine specificities of these anti-GXM an-
tibodies and gain further insight into the antibody binding
site, we have used phage display peptide libraries to obtain
peptide mimetics of GXM epitopes. For example, the pro-
tective IgG1 2H1 bound to several peptide motifs (20).
Two of these motifs (2H1 motif 1, (E)TPXWM/LM/L;
and 2H1 motif 2, W/YXWM/LYE) cross-reacted with
many anti-GXM antibodies, but not with 13F1. The
three-dimensional structure of 2H1 bound to a peptide of
2H1 motif 1 showed the antibody binding site to be a hy-
drophobic pocket that was largely, but not completely, oc-
cupied by the peptide (Young, A.C.M., P. Valadon, A.
Casadevall, M.D. Scharff, and J.C. Sacchetini, manuscript
in preparation). Most sequences identified by both mAbs
12A1 and 13F1 contain three aromatic amino acids, each
separated by one residue. This pattern (ArXArXAr) was
also present in peptides selected by 2H1 (20) indicating that
mAbs 12A1 and 13F1 bound peptides at the same location
in the antibody binding pocket and probably in a similar
way. More precisely, just as with the 2H1 motifs, there is
probably a type II b turn in the backbone of the bound
form of the peptide since such a structure is required to fit
the anti-GXM antibody binding pocket (Young, A.C.M.,
P. Valadon, A. Casadevall, M.D. Scharff, and J.C. Sacchetini,
manuscript in preparation). As a result, the peptide residues
group in a compact structure with all lateral chains pointing
down toward the binding pocket where they are in close
contact with the antibody residues.
The peptides selected by 12A1 and 13F1 from two dif-
ferent phage libraries could be grouped into three sets ac-
cording to their sequence and their reactivity with the
mAbs. Group 1 peptides bind only 12A1 and share the mo-
tif W/YXW/YXW/YE. This motif is reminiscent of the
2H1 motif W/YXWM/LYE (20) and contains fM2, a phage
bearing a peptide sequence identical to fG3, a phage that
had been isolated previously by mAb 2H1. Phage fG3 was
already noted to have the largest cross-reactivity among
anti-GXM antibodies. In fact, cross-screening of the deca-
peptide library with several anti-GXM antibodies shows
that the 2H1 motif W/YXWM/LYE can define the epi-
tope bound by most anti-GXM mAbs elicited by GXM-TT
(Valadon, P., and M.D. Scharff, manuscript in preparation).
mAb 12A1 reacts with peptides of this motif, gives the
same fluorescent pattern as 2H1 on serotypes A and D, and
has a similar protective effect. This suggests that 12A1 and
2H1 bind to the same protective epitope which is located
on the outer part of the cryptococcal capsule. On the other
hand, mAb 13F1 did not cross-react with any of the 2H1-
isolated phage (20), but isolated group 2 phage bearing a
specific sequence motif (WLW[E]W) that is distinguished
from group 1 by the leucine between the first two aromatic
residues and the absence of tyrosine. This result suggests the
presence of a significant structural difference in 13F1 bind-
Figure 4. Opsonic activity of mAbs 12A1 and 13F1 in the presence of
J774.16 macrophages on (A) C. neoformans serotype D strain 24067, and
(B) C. neoformans serotype A strain J11.692 Epitope Location in Cryptococcus neoformans and Antibody Efficacy
ing site that makes the specificity of 13F1 distinct from
12A1 or related antibodies like 2H1.
When examined by indirect immunofluorescence using
confocal microscopy, mAb 12A1 bound to the outer rim of
the polysaccharide capsule giving an annular pattern of
binding, while mAb 13F1 bound in discrete areas through-
out the capsule with a punctate pattern of binding. IEM re-
vealed a structural heterogeneity in the polysaccharide cap-
sule of C. neoformans with an outer rim connected to the
cell wall by spoke-like structures. According to the indirect
immunofluorescence observation, mAb 12A1 bound to the
outer rim part of the capsule. On the other hand, 13F1 bind-
ing occurred at the outer rim but was also distributed through-
out the capsule and almost reached sites alongside the cell wall
(Fig. 2). Since all of these results were obtained with poly-
meric IgM antibodies in indirect assays using anti-IgM an-
tisera, it is not clear whether these structures exist as such,
are the result of flexible polysaccharide molecules bearing
distinct epitopes that may be present in different densities,
or are located in different parts of the capsule and are aggre-
gated by decavalent IgM antibodies. We have not identified
IgG antibodies that bind with high enough affinity to the
13F1 epitope to allow us to generate Fab9 molecules that could
be used in direct immunofluorescence to resolve this issue.
The punctate pattern of binding with mAb 13F1 was
observed on other serotype D organisms, except for the J22
strain which has an unusual polysaccharide structure con-
sisting of a novel triad repeat (16). In contrast, mAbs 12A1
and 13F1 both produced annular fluorescence patterns when
bound to serotype A strains. The change in mAb 13F1
binding pattern from punctate to annular correlated with a
shift from nonprotective or even enhancing on serotype D,
to protective on serotype A. This led us to the hypothesis
that annular binding was associated with enhanced phago-
cytosis and protection, and suggested that the binding of
the IgM molecule to the surface of the organism was criti-
cal for Fc-mediated effector functions.
The ability of mAbs 12A1 and 13F1 to opsonize C. neo-
formans was studied on J774.16 cells, a well-established
macrophage-like cell line with antibody-mediated anticryp-
tococcal activity (25). mAb 12A1 was more effective than
mAb 13F1 in promoting phagocytosis of serotype A and D
organisms, and annular binding was associated with an in-
crease in the ability of mAb 13F1 to opsonize C. neoformans
for phagocytosis. The mechanism by which IgM opsonize
C. neoformans in the absence of complement is not under-
stood, but could be due to an unrecognized IgM receptor
on J774.16 cells, mAb-induced structural changes in the
polysaccharide capsule that reduce its inherent antiphago-
cytic properties, or complement-mediated phagocytosis us-
ing complement synthesized by the macrophage-like cell
(29). Whatever the mechanism, the phagocytosis results in-
dicate that annular and punctate binding to the polysaccha-
ride capsule are associated with differences in opsonization.
In vivo, IgM mAbs like 12A1 may enhance clearance of
fungal cells by fixing complement component C3b which
serves as a potent opsonin for C. neoformans (30). mAb 13F1
appears to be both near the surface and sequestered within
the capsule at locations where it may interact with comple-
ment in a different manner (31). These results are similar to
the finding of Jones and Fischetti (2) that the location of
mAb binding within the M6 surface protein of group A
streptococci determined whether or not an mAb effectively
opsonized bacteria. It has also been shown that epitope
density may influence the ability of the Fc region to acti-
vate complement (32). Despite seemingly similar binding
densities of 12A1 and 13F1 on the immunoelectron micro-
graphs, it is important to note that IEM is an indirect assay
and the actual epitope densities of mAbs 12A1 and 13F1
could be quite different.
When we examined 16 additional anticryptococcal mAbs
with closely related V region sequences for their binding
pattern to polysaccharide capsule, only the IgM mAb 21D2,
which is also not protective against serotype D infection,
produced a binding pattern on serotypes D and A similar to
that of mAb 13F1. While mAb 13F1 was isolated in re-
sponse to immunization with GXM-TT, mAb 21D2 arose
in response to infection, demonstrating that nonprotective
antibodies can arise naturally as well as in response to im-
munization (18). Based on fluorescence pattern alone, it is
impossible to determine whether mAbs 13F1 and 21D2
bind the same epitope. We tried to link 21D2 to 13F1 or
12A1 by sequential selection of peptide on phage using the
mAbs. This resulted in the isolation of group 3 peptides
that reacted identically with the three mAbs (Table 1), but
did not show any cross-reactivity with a large panel of anti-
GXM antibodies (data not shown). However, de-O-acety-
lation of serotype D GXM causes a loss of binding for mAb
13F1, but not for 21D2, suggesting that they have different
fine specificities and could even bind distinct epitopes (33).
mAbs 13F1 and 21D2 use the same Vk5.1 gene but distinct
members of the VH7183 gene family. Among 29 BALB/c
mAbs recovered from three separate fusions, mAbs 13F1 and
21D2 share a common somatic mutation at position 33 in the
heavy chain converting a phenylalanine in the consensus se-
quence to a tyrosine. This shared tyrosine may be responsible
for a shift in interaction with cryptococcal polysaccharide.
Cherniak et al. demonstrated structural variations in the
capsular GXM from initial and relapse isolates recovered
from individual patients (16). In particular, they identified a
patient with an initial isolate that was serotype A/D, sero-
type A at the time of the first relapse, and then serotype D
at the time of the second relapse. This observation sug-
gested that variations in polysaccharide structure among se-
quential isolates from one patient may reflect selective in-
fluences of the host immune system. Our observation
provides a mechanism by which changes in serotype could
happen in vivo. Protective antibodies could select antigenic
variants of C. neoformans which neutralize antibody by se-
questration at sites where it is unable to carry out effective
protective functions. This phenomenon, if it occurs during
infection, has important implications for the design of vac-
cines and the use of passively administered mAbs in crypto-
coccal infection. The results presented here emphasize the
importance of evaluating the protective potential of anti-
bodies on multiple representatives of different strains.693 Nussbaum et al.
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